0000899243-20-007676.txt : 20200309
0000899243-20-007676.hdr.sgml : 20200309
20200309193735
ACCESSION NUMBER: 0000899243-20-007676
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200305
FILED AS OF DATE: 20200309
DATE AS OF CHANGE: 20200309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lehrer-Graiwer Joshua
CENTRAL INDEX KEY: 0001789673
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 20699550
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 171 OYSTER POINT BLVD., SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-05
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001789673
Lehrer-Graiwer Joshua
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Common Stock
2020-03-05
4
S
0
1138
65.30
D
2595
D
Common Stock
2020-03-09
4
M
0
938
19.89
A
3533
D
Common Stock
2020-03-09
4
S
0
938
59.90
D
2595
D
Stock Option (Right to Buy)
19.89
2020-03-09
4
M
0
938
0.00
D
2026-09-07
Common Stock
938
1875
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
Represents the weighted average sale price of the shares sold ranging from $59.80 to $60.00 per share, inclusive. The Reporting Person will provide, upon request by the Issuer, a security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares of Common Stock underlying the option shall vest in 16 equal quarterly installments over 4 years from September 8, 2016, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/Tricia Suvari , as Attorney-in-Fact
2020-03-09